COVID-19 vaccination in patients with classic and variant hairy cell leukemia

Robert J. Kreitman , Lacey James , Julie Feurtado , Holly Eager , Olena Sierra Ortiz , Mory Gould , Isaac Shpilman , Hong Zhou , Peter D. Burbelo , Jeffrey I. Cohen , Hao-Wei Wang , Constance M. Yuan , Evgeny Arons
{"title":"COVID-19 vaccination in patients with classic and variant hairy cell leukemia","authors":"Robert J. Kreitman ,&nbsp;Lacey James ,&nbsp;Julie Feurtado ,&nbsp;Holly Eager ,&nbsp;Olena Sierra Ortiz ,&nbsp;Mory Gould ,&nbsp;Isaac Shpilman ,&nbsp;Hong Zhou ,&nbsp;Peter D. Burbelo ,&nbsp;Jeffrey I. Cohen ,&nbsp;Hao-Wei Wang ,&nbsp;Constance M. Yuan ,&nbsp;Evgeny Arons","doi":"10.1016/j.bneo.2024.100035","DOIUrl":null,"url":null,"abstract":"<div><h3>Abstract</h3><div>Patients with the B-cell malignancy hairy cell leukemia (HCL) and the poorer-prognosis variant HCLv often receive anti-CD20 monoclonal antibodies (mAbs), which kill normal B cells, impairing humoral immunity. We measured COVID-19 antibodies after doses of COVID-19 vaccine in patients with HCL (n = 415) and HCLv (n = 32). After the second COVID-19 vaccine dose, spike antibody level most strongly correlated with normal B-cell levels (r = 0.365, <em>P</em> &lt; .0001), followed by CD4<sup>+</sup> T-cell count (r = 0.244, <em>P</em> = .0002), and was less related to immunoglobulin G level (r = 0.101, <em>P</em> = .14). Spike antibody also correlated with normal B cells after the third to fifth vaccine doses and with CD4<sup>+</sup> count after the third dose. Normal B-cells were undetectable in 87% of patients within 6 months after the last dose of anti-CD20 mAb and were lower than in patients at 6 to 12 months (<em>P</em> = .0003), which, in turn, were lower than at 12 to 18 months (<em>P</em> = .0002). Infection with COVID-19 became more common after use of the third vaccine dose; spike antibody levels were higher in patients with prior infection (positive vs negative nucleocapsid antibodies; <em>P</em> &lt; .0001). Spike antibodies decreased faster after ibrutinib or anti-CD20 mAb. We conclude that decreased levels of normal B cells in patients with HCL/HCLv, due to disease and/or anti-CD20 therapy, are associated with lower COVID-19 vaccination efficiency and such patients may not respond well to vaccines. The associated studies were registered at <span><span>www.ClinicalTrials.gov</span><svg><path></path></svg></span> as #NCT01087333 (HCL/HCLv) and #NCT04362865 (COVID-19).</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100035"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Neoplasia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2950328024000359","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Patients with the B-cell malignancy hairy cell leukemia (HCL) and the poorer-prognosis variant HCLv often receive anti-CD20 monoclonal antibodies (mAbs), which kill normal B cells, impairing humoral immunity. We measured COVID-19 antibodies after doses of COVID-19 vaccine in patients with HCL (n = 415) and HCLv (n = 32). After the second COVID-19 vaccine dose, spike antibody level most strongly correlated with normal B-cell levels (r = 0.365, P < .0001), followed by CD4+ T-cell count (r = 0.244, P = .0002), and was less related to immunoglobulin G level (r = 0.101, P = .14). Spike antibody also correlated with normal B cells after the third to fifth vaccine doses and with CD4+ count after the third dose. Normal B-cells were undetectable in 87% of patients within 6 months after the last dose of anti-CD20 mAb and were lower than in patients at 6 to 12 months (P = .0003), which, in turn, were lower than at 12 to 18 months (P = .0002). Infection with COVID-19 became more common after use of the third vaccine dose; spike antibody levels were higher in patients with prior infection (positive vs negative nucleocapsid antibodies; P < .0001). Spike antibodies decreased faster after ibrutinib or anti-CD20 mAb. We conclude that decreased levels of normal B cells in patients with HCL/HCLv, due to disease and/or anti-CD20 therapy, are associated with lower COVID-19 vaccination efficiency and such patients may not respond well to vaccines. The associated studies were registered at www.ClinicalTrials.gov as #NCT01087333 (HCL/HCLv) and #NCT04362865 (COVID-19).
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
为典型和变异毛细胞白血病患者接种 COVID-19 疫苗
摘要B细胞恶性肿瘤毛细胞白血病(HCL)和预后较差的变异型HCLv患者经常接受抗CD20单克隆抗体(mAbs)治疗,这种抗体会杀死正常B细胞,损害体液免疫。我们在HCL(415人)和HCLv(32人)患者注射COVID-19疫苗后测量了COVID-19抗体。第二剂 COVID-19 疫苗接种后,尖峰抗体水平与正常 B 细胞水平的相关性最强(r = 0.365,P < .0001),其次是 CD4+ T 细胞计数(r = 0.244,P = .0002),与免疫球蛋白 G 水平的相关性较小(r = 0.101,P = .14)。尖峰抗体还与第三至第五剂疫苗接种后的正常 B 细胞以及第三剂疫苗接种后的 CD4+ 细胞计数相关。87%的患者在最后一剂抗CD20 mAb后6个月内检测不到正常B细胞,低于6至12个月时的水平(P = .0003),而后者又低于12至18个月时的水平(P = .0002)。使用第三剂疫苗后,COVID-19 感染变得更加常见;之前感染过的患者的尖峰抗体水平更高(核头抗体阳性与阴性;P < .0001)。使用伊布替尼或抗 CD20 mAb 后,尖峰抗体下降更快。我们的结论是,由于疾病和/或抗CD20治疗,HCL/HCLv患者正常B细胞水平下降与COVID-19疫苗接种效率降低有关,这类患者可能对疫苗反应不佳。相关研究已在 www.ClinicalTrials.gov 注册,注册号为 #NCT01087333(HCL/HCLv)和 #NCT04362865(COVID-19)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Pharmacological targeting of CBX7 alters the epigenetic landscape and induces differentiation of leukemic cells Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma Development and characterization of a low-affinity humanized CD19 chimeric antigen receptor for B-cell malignancies Deciphering MARCH5’s impact on multiple myeloma: insights into autophagy regulation and AKT-FOXO3 signaling Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1